or Try an Advanced Search...

    ETF Components for ARKG - ARK Genomic Revolution Multi-Sector ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    TWST C 2.62 8.58
    CRSP F -0.59 6.66
    CDNA B -3.77 6.09
    RXRX D -6.65 5.87
    NTLA D -3.26 4.38
    SDGR F -1.19 3.84
    BEAM F -1.12 3.55
    ARCT B 0.86 3.51
    IONS F 2.79 3.50
    MRNA B -5.90 3.48
    TXG F 0.04 3.23
    EXAS F 0.44 3.09
    VCYT D -1.14 3.04
    DNA F -5.51 2.98
    NRIX C 1.09 2.93
    ACCD F -1.12 2.91
    TDOC F -0.44 2.70
    VRTX B 2.77 2.65
    VEEV D -10.27 2.63
    ADPT D -4.43 2.61
    MASS D 2.27 1.86
    PACB F -7.73 1.69
    INCY C 0.86 1.57
    QSI F -2.56 1.54
    PRME D -0.31 1.44
    AMGN C 1.61 1.32
    REGN B 1.06 1.17
    VERV F 0.97 1.16
    CMPS F -0.54 1.14
    CERS D -2.19 1.09
    PATH F 1.57 1.05
    ABSI D -0.94 1.01
    BFLY D -0.51 0.78
    RPTX F 3.88 0.64
    PSNL D -0.76 0.61
    GH B -1.35 0.61
    NTRA A -3.26 0.59

    Represented by ETF Holdings

    Keywords: Biotechnology Cancer Biopharmaceutical Drug Discovery Life Sciences Biology Medicine Genetics Genomics Nasdaq 100 S&P 500 Telehealth Telemedicine Molecular Biology Precision Medicine Acid Blood Test Breakthrough Therapy CRISPR Cholesterol
    Industries: Biotechnology Diagnostics & Research Health Information Services Health Information Services Medical Devices Drug Manufacturers - Major Medical Care Facilities Software - Infrastructure

    Recent News for ARK Genomic Revolution Multi-Sector ETF & its Holdings

    Date Stock Title
    May 31 MRNA Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
    May 31 MRNA Moderna Gets FDA Approval For Respiratory Syncytial Virus Vaccine for Seniors
    May 31 CMPS Psychedelic stocks mixed as FDA comments on MDMA therapy (update)
    May 31 IONS Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
    May 31 MRNA Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars
    May 31 MRNA Moderna Looks for Boost From Newly Approved RSV Shot
    May 31 MRNA Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
    May 31 NTRA (NTRA) - Analyzing Natera's Short Interest
    May 31 PATH Stock Market Retreats As Salesforce, Dell Lead Earnings Losers: Weekly Review
    May 31 INCY Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
    May 31 REGN FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
    May 31 MRNA Moderna wins FDA approval for RSV vaccine
    May 31 VRTX Analyst Expectations For Vertex Pharmaceuticals's Future
    May 31 MRNA Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
    May 31 VEEV Biggest stock movers today: GPS, PD, VEEV, DELL, MDB, and more
    May 31 VEEV Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up
    May 31 REGN FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
    May 31 PATH UiPath First Quarter 2025 Earnings: EPS Misses Expectations
    May 31 PSNL Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
    May 31 VEEV QUALCOMM To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday
    Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
    Exchange Traded Fund ETF Biotechnology Stem Cell Genomics Bioinformatics
    Back to the Main ARKG Page...